Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Losartan for treatment of erectile dysfunction

May 24, 1996

Vasomax completes phase II in Germany

May 24, 1996

MacroChem's erectile dysfunction therapy moves to phase I/II in U.S.

May 24, 1996

Takeda claims antidiabetic and hypolipidemic agents

May 24, 1996

Role of p140 in diabetes investigated by Ono

May 24, 1996

PolyHeme phase II results in trauma patients announced

May 24, 1996

RF-1051 receives orphan drug status in PWS

May 24, 1996

Amgen begins clinical testing of leptin

May 24, 1996

Intrachol receives U.S. patent protection

May 24, 1996

Orphan Medical discontinues glucaric acid development

May 24, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 30, 2026
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....